Innopharmax

Innopharmax EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Innopharmax (4172.TWO) as of Oct 16, 2026 is -13.12. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -19.44 — a change of -32.51% (higher).

EV/OCF

-13.12

YoY

-32.51%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Innopharmax is 2025 -13.12 . EV/OCF (Enterprise Value to Operating Cash Flow) of Innopharmax was 2024 -19.44 . It decreases by -32.51% higher compared to the previous year.

The Innopharmax EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-23.67 TWD
Jan 1, 2019
-38.30 TWD
Jan 1, 2020
-32.69 TWD
Jan 1, 2021
-31.56 TWD
Jan 1, 2022
-16.92 TWD
Jan 1, 2023
-33.56 TWD
Jan 1, 2024
-19.44 TWD
Jan 1, 2025
-13.12 TWD
The Innopharmax EV/OCF history
YEAREV/OCFYoY
-13.12-32.51%
-19.44-42.06%
-33.56+98.28%
-16.92-46.38%
-31.56-3.45%
-32.69-14.65%
-38.30+61.79%
-23.67+76.17%
-13.44+32.85%
-10.12-11.19%
-11.39-68.62%
-36.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innopharmax Stock analysis

What does Innopharmax do? Innopharmax Inc is a pharmaceutical company based in Taipei City, Taiwan. It develops and commercializes pharmaceutical products, primarily focusing on oncology and specialty treatments. The company went public on September 13, 2012. It offers generic drugs such as Cyclosporine A, Tacrolimus, Imipenem, Cilastatin, Gadodiamide, Gadopentetate, Levodopa, Carbidopa, and Entacapone, as well as new drugs including Gemcitabine Oral, Bendamustine, AB01001 patch, and Carvedilol CR. Innopharmax has 34 employees and distributes its products mainly within Taiwan. Innopharmax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innopharmax stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Innopharmax is -13.12 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Innopharmax changed from -19.44 to -13.12, representing a -32.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Innopharmax since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Innopharmax with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Innopharmax

All Key Metrics — Innopharmax